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Cis-elements which control human papillomavirus early gene expression have previously been localized to sequences in
the upstream regulatory region (URR) which are proximal to the E6 open reading frame. These elements include an enhancer
element which functions preferentially in keratinocytes as well as promoter elements. The function of the remaining approxi-
mate 500-bp region of the URR in regulating viral expression in the high risk papillomaviruses has been largely uncharacterized.
In HPV 6, a negative regulator of early expression, or silencer, has been identified in this 5* region of the URR. In this study,
we have investigated the role of the 5* portion of the HPV 31 URR in regulating viral expression. Sequences in this region
were found to exert a minimal negative effect on homologous or heterologous promoters. In contrast, a 128-bp sequence
within this region was found to exhibit enhancer activity on heterologous and homologous promoters. This enhancer also
augmented the activity of the previously identified minimum keratinocyte enhancer. The cellular factors, YY1 and TEF-1, were
determined by DNase I footprint analysis and electrophoretic mobility shift assays (EMSAs) to bind the 128-bp enhancer.
The binding of YY1 to two of these sites was found to be important for enhancer activity. q 1997 Academic Press
INTRODUCTION nation of ubiquitous factors such as AP-1 (Chan et al.,
1990; Kyo et al., 1995), NFI (Apt et al., 1993, 1994), TEF-1
Human papillomaviruses (HPVs) are etiological agents (Ishiji et al., 1992), Oct-1 (O’Connor et al., 1995b), C/EBP-
of proliferative epithelial lesions and over 70 distinct types b (Kyo et al., 1993), and YY1 (Bauknecht et al., 1992, 1995,
have been isolated to date (van Ranst et al., 1996). About 1996; Dong et al., 1994; May et al., 1994; O’Connor et al.,
one-third of all HPVs specifically infect the mucosal epithe- 1996). Additional studies have indicated that the interac-
lium of the anogenital tract, and types 16, 18, and 31 are tions between TEF-1 and a coactivator (Ishiji et al., 1992),
associated with increased risk for cervical cancer (Lorincz Sp1 and Sp3 (Apt et al., 1996), or YY1 and C/EBP-b (Bauk-
et al., 1986; Macnab et al., 1986; Pfister, 1987). The E6 necht et al., 1996), contribute to enhancer activity specifi-
and E7 genes of the high risk HPVs encode oncoproteins cally in keratinocytes.
(Bedell et al., 1989; Matlashewski et al., 1987; Phelps et The URRs of genital HPVs exhibit similarities in the
al., 1988; Watanabe et al., 1989) which interact with the locations of four E2 binding sites, three of which are
cell cycle regulatory proteins p53 (Scheffner et al., 1990;
located proximal to the E6 open reading frame while
Werness et al., 1990) and retinoblastoma (Barbosa et al.,
the fourth is found approximately 500 base pairs (bp)
1990; Dyson et al., 1989), respectively. The expression of
upstream (Fig. 1A). The 3* region of the URR contains a
HPV transforming genes is regulated by viral and cellular
promoter which consists of sites for the cellular factors
factors which bind to sequences located upstream of E6
Sp1 and TFIID as well as binding sites for the viral factors
gene, in the upstream regulatory region (URR) (Cripe et
E1 and E2 (Tan et al., 1994). This region also contains
al., 1987; Gius et al., 1988; Gloss et al., 1987; Thierry et
elements for the replication and episomal maintenance
al., 1987). The spectrum of cellular factors binding to the
of viral genomes (DelVacchio et al., 1992). Early viralURR is thought to be a major determinant of the epithelial
transcripts initiate at a promoter, designated p97 intropism of HPVs, and significant effort has been made to
HPV31, which is located just upstream of the E6 AUG.identify the factors responsible for transcriptional regula-
Located approximately 150 bp upstream of p97 is thetion. Some reports have suggested the existence of kera-
major enhancer which contains binding sites for numer-tinocyte-specific cellular factors such as KRF-1 in HPV18
ous transcriptional activators (Fig. 1A). Similar enhancers(Mack et al., 1991) or CEII in HPV11 (Chin et al., 1989)
have been identified in all genital papillomavirus typeswhich contribute to epithelial tropism. An alternative expla-
which have been examined. This region has been callednation for this tropism is that it is due to the various combi-
the keratinocyte-derived enhancer for HPV16 (Cripe et
al., 1987), the constitutive enhancer for HPV18 (Gius et
al., 1988), and the minimum enhancer for HPV31 (Kyo et1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (312) 503-1339. E-mail: lal@merle.acns.nwu.edu. al., 1995). This enhancer is able to activate expression
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of heterologous promoters preferentially in keratinocytes. Both cell lines were grown in E media in the presence of
mitomycin C-treated 3T3 J2 cells as described previouslyThe role of the region of the URR, which is approximately
500 bp in length, between the minimum enhancer and (Bedell et al., 1991; McCance et al., 1988).
L1 gene has not yet been established. Sequences proxi-
Plasmidsmal to the L1 open reading frame are likely to contain
signals for polyadenylation and termination of late tran-
Luciferase reporter constructs were made in the
scripts. One study has suggested that this region con-
pGL3Basic and pGL3Promoter (Promega, Madison, WI)
tains a suppressor function for early expression which
backgrounds. Various HPV31 URR fragments were syn-
is relieved following differentiation (Roman et al., 1995).
thesized by PCR so as to include sites for cloning at
In HPV31, the deletion of this 5* region of the URR re-
either end. An MluI site was inserted at the 5* end and
sulted in slightly increased reporter gene expression as
a BglII site was included at the 3* end. These inserts
compared to the whole URR (Kyo et al., 1995). In this
were ligated upstream of the luciferase reporter gene,
study, we have examined the role of this region in regu-
pGL3Basic (no promoter) for constructs which utilized
lating HPV31 early expression.
p97 promoter, or into pGL3Promoter (SV40 promoter) to
The 5* region of HPV31 URR contains two distinct types
test for enhancer activity. These plasmids were desig-
of sequences. The first is long alternating thymidine (T)
nated by the length of the inserts in base pairs and the
and purine (A or G) sequence, which has sequence simi-
abbreviation pBas or pPro (Figs. 1A and 6A). The reporter
larities to the transcriptional silencer reported in HPV6
plasmids containing internal deletions (pBas102del and
(Roman et al., 1995; Fig. 1A). This sequence in HPV31 is
pBas128del; Fig. 1A) were constructed by first inserting
about 200 bp in length and the cytidine (C) content on
a BamHI site at each end by PCR followed by subcloning.
the sense strand is less than 5%. The second region
A reporter containing two tandem repeats of a 128-bp
contains three putative YY1 and one TEF-1 binding sites.
fragment (pPro128w; Fig. 6A) was made by multimerizing
YY1 is an unusual transcriptional factor which can act
PCR-derived fragments containing EcoRI ends. Site-di-
as either a repressor or an activator dependent on the
rected mutagenesis was performed to introduce substitu-
promoter context (Shi et al., 1991), as well as through
tion mutations in the YY1 and TEF-1 binding sites (Fig.
interaction with other transcriptional factors such as C/
5A) as described previously (Higuchi et al., 1988). The
EBP-b (Bauknecht et al., 1996). The consensus binding
nucleotide (nt) numbering of HPV31 sequence is ac-
site for YY1 contains the core motif, CAT, but the flanking
cording to Goldsborough et al. (1989). All plasmids were
sequences vary. It is therefore difficult to identify actual
verified by DNA sequencing with T7 Sequenase version
YY1 binding sites by sequence analysis alone, though
2.0 (Amersham, Arlington Heights, IL) to confirm that the
high affinity binding sites can be determined by PCR-
inserts contained the expected mutations.
assisted binding site selection (Hyde-DeRuyscher et al.,
1995; Yant et al., 1995). TEF-1 has been identified as a DNA transfection and luciferase assay
transactivator which may play a role in regulating HPV16
transcription (Ishiji et al., 1992), and a consensus binding Transient transfection of luciferase reporter plasmids
into the keratinocyte cell lines was performed using Lipo-site is present in the 5* region of HPV31 URR as deter-
mined by sequence analysis. fect AMINE (Gibco, Gaithersburg, MD), according to the
protocol recommended by the manufacturer. Briefly, 5 1In the present study, we have investigated the function
of 5* region of HPV31 URR in epithelial cell lines and 105 cells were seeded in a 60-mm tissue culture dish
and allowed to grow to approximately 50% confluence.observed that sequences within this region function as
enhancers, which augment the activity of the minimum The DNA–lipid complex contained 3 mg of luciferase
reporter plasmid and 0.5 mg of pSV-b-Galactosidaseenhancer. While this region bears similarity to the HPV6
silencer, it does not exhibit significant suppressor activ- Control Vector (Promega), which was then mixed with
300 ml of Opti-MEM (Gibco) and 15 ml of Lipofect AMINEity. The 128-bp enhancer appears to be dependent upon
YY1 and TEF-1 binding for its activity. with 300 ml Opti-MEM mixture. This mixture was then
incubated at room temperature for 30 min, placed onto
washed cells, and incubated for 5 hr at 377. At this time,MATERIALS AND METHODS
3 ml of 10% FBS E media was added to the cells and
Cell culture
the mixture was incubated for an additional 16 hr. The
cells were harvested 48 hr after the transfection. ExtractsTwo cell lines SCC-13 and CIN612 cells are of squa-
mous epithelial origin and were used in this study. The for luciferase assays were made using 400 ml Reporter
Lysis Buffer (Promega) and luciferase activity was mea-SCC-13 cell line was derived from a squamous cell carci-
noma of the skin and lacks HPV sequences (McCance sured with a Monolight 2010 luminometer (Analytical Lu-
minescence Laboratory, San Diego, CA). b-galactosi-et al., 1988; Rheinwald et al., 1981). The CIN612 cell line
was derived from cervical intraepithelial neoplasia type 1 dase assay was also performed with the same cell ex-
tract to standardize for transcriptional efficiency. Alllesion (CIN I) that maintains a subtype of HPV31 (HPV31b)
DNA as episomes (Bedell et al., 1991; Rader et al., 1990). experiments were performed at least three times in each
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plasmid and represent the relative luciferase activity as of the 128-bp region as an enhancer was seen equally
in both cell lines. We conclude that sequences within aaverage and a standard deviation.
128-bp region in the 5* region of the HPV31 exhibit en-
hancer activity in transient assays.DNase I footprint analysis and electrophoretic
mobility shift assay (EMSA) A 236-bp region (nt 7045–7281) of the URR contains
an alternating thymidine–purine sequence which is simi-
Preparation of SCC-13 nuclear extracts was according lar in composition to a recently identified silencer ele-
to the method of Dignam et al. (1983). The procedures ment in HPV6. Deletion of this sequence from the URR
of DNase I footprint analysis and EMSAs were previously (pBas747 (nt 7281–116)) did not result in a significant
described (Kyo et al., 1995). The probe used for DNase increase in expression. Similarly, when this region was
I footprint analysis was a 228-bp fragment (nt 7333–7561; cloned upstream of a heterologous promoter, it failed
Fig. 1A) of HPV31 URR which was end-labeled. Titrations either to activate or suppress expression. While a slight
of nuclear extract (0, 5, 20, 40 mg) and DNase I (20, increase in viral expression was seen in plasmids lack-
40, 80, 160 ng/ml) were performed to similar levels of ing this sequence, the effect was minimal. If a silencer
cleavage. For EMSAs, 10 mg of SCC-13 nuclear extract is present in this region, it is only weakly active in our
was incubated with the labeled probe and all competitors transient assays. Similarly, deletion of sequences be-
were added at 100-fold excess of the probe. For antibody tween nt 7281 and 7383 also resulted in a slight increase
supershift assays, 1 mg of antibody was incubated with in viral expression.
10 mg nuclear extract for 60 min on ice, followed by the
incubation with labeled probe and gel electrophoresis.
Three YY1s and one TEF-1 bind to the 128-bpConsensus binding sites oligonucleotides for TEF-1, AP-
enhancer region1, Oct-1, NFI, and Sp1 were as previously described (Kyo
et al., 1995). The YY1 consensus binding site oligonucleo- We next sought to identify the nuclear factors which
tide (5*-CGCTCCGCGGCCATCTTGGCGGCTGGT-3*) and bound the 128-bp enhancer region of HPV31 URR. First,
antibodies against YY1, Oct-1, and Sp1 were purchased we performed a DNase I footprint analysis on the 228-
from Santa Cruz (Santa Cruz, CA). bp fragment (nt 7333–7561; Fig. 1A) which contains the
enhancer region. As shown in Fig. 2, following incubation
RESULTS with nuclear extracts from SCC-13 cells, several bands
which were diminished in intensity following DNase IThe 5* region of HPV31 URR functions as a
treatment which was likely due to the presence of boundtranscriptional enhancer
proteins. A sequence analysis of the 128-bp region re-
vealed the presence of consensus YY1 (Hyde-DeRu-To investigate the function of sequences located in
the 5* region of the HPV31 URR, we constructed a series yscher et al., 1995; Yant et al., 1995) and TEF-1 (Ishiji et
al., 1992) binding sites which corresponded closely toof reporter plasmids containing portions of the upstream
regulatory region (Fig. 1A). Each plasmid was transfected the protected regions. Additional minor DNase I-sensitive
bands which are decreased by increased amount of ex-into two different cell lines of squamous epithelial origin,
SCC-13 and CIN612 cells. The results of at least three tract were also observed, but these do not correspond
to known transcriptional factors. It is possible additionaltransfections with the corresponding variations are
shown in Figs. 1B–1E. When the entire 5* region (466 bp; uncharacterized factors bind to these sequences.
To identify the factors binding these regions, we nextnt 7045–7511) of HPV31 URR was deleted from reporters
containing the entire URR, a significant reduction in activ- performed EMSAs using probes 1– 4 as shown in Fig.
3. These sequences contain putative binding sites fority was observed (pBas983 (nt 7045–116) vs pBas517 (nt
7511–116)). The most significant decrease was observed YY1 and TEF-1. The result of EMSA using probe 1 is
shown in Fig. 4A. Three shifted bands were observedwhen sequences between nt 7383 and 7511 were de-
leted. When sequences between nt 7045 and 7511 were using the SCC-13 nuclear extract, and the fastest and
the slowest migrating bands were diminished by thecloned upstream of the heterologous SV40 promoter, a
two- to threefold activation was observed in transient addition of a YY1 consensus binding site as well as
homologous competitor. The middle band was not af-assays. This activation ability was localized to a 128-bp
region between nt 7383 and 7511. When transfections fected by the presence of these competitors and binding
appeared enhanced by the presence of homologouswere performed in CIN612 cells which contain endoge-
nous HPV31b sequences, similar effects were observed competitor DNA. Additional competition analyses per-
formed with mutation of the putative YY1 binding siteupon deletion of the 5* region (Fig. 1D). In these cells, a
sixfold activation over background was observed with did not alter the binding pattern. We conclude that the
fastest and the slowest migrating bands were due toplasmids containing the 128-bp region (nt 7383–7511)
cloned upstream of a SV40 heterologous promoter. It is the binding of YY1 and probe DNA. The middle band
appeared to be the result of nonspecific binding. Wheninteresting to note that plasmid pPro230 has activity in
SCC-13 cells but not CIN612 cells. However, the activity a supershift assay was performed with an anti-YY1 anti-
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FIG. 1. A schematic representation of plasmid constructs and the results of transient expression assays. (A) Binding sites for various transcriptional
factors on the URR were described previously (Kyo et al., 1995; O’Connor et al., 1995a). Binding sites for YY1 and TEF-1 were identified by sequence
analyses (Hyde-DeRuyscher et al., 1995; Yant et al., 1995; Ishiji et al., 1992). A long thymidine and purine alternating region with sequence similarities
AID VY 8771 / 6a4f$$8771
09-25-97 11:40:52 viral AP: VY
163THE FUNCTION OF 5* REGION OF HPV31 URR
body, the slowest migrating band was completely
shifted, while the fastest migrating band was diminished
in intensity (Fig. 4A). No change was seen when antibod-
ies against Oct-1 and Sp1 were added to the extracts
(Fig. 4A). We conclude that YY1, by itself or in a complex
with other proteins, bound to site 1.
The results of EMSAs with probes 2 and 3 demon-
strated a similar binding of YY1 (Figs. 4B and 4C). Two
shifted bands were observed in each case using SCC-
13 nuclear extract and both bands were diminished by
the addition of YY1 consensus binding sites or homolo-
gous competitor DNAs. Competition with binding sites 2
and 3 which contained mutations in the putative YY1
binding site, failed to diminish the intensity of the sifted
band as did competition assays with oligonucleotides
containing other factor binding sites (Figs. 4B and 4C).
As in the case with site 1, supershifted bands were ob-
served following addition of anti-YY1 antibodies, indicat-
ing that probes 2 and 3 bound YY1 either by itself or
in a complex with other proteins. The supershift is not
complete and we believe this is a characteristic of the
antibody as well as the concentration used. To investi-
gate whether YY1 bound to site 1, 2, and 3 by itself or
in complex with cellular proteins, we performed gel shift
analysis using a consensus YY1 binding site (Fig. 4D).
Similar shifts were observed with all four probes, indicat-
ing that YY1 likely binds these sites by itself. The faster
migrating band is likely a degradation product.
Binding site 4 contains a putative TEF-1 binding site,
and two shifted bands were observed by EMSA using
SCC-13 nuclear extracts (Fig. 4E). The slower migrating
band was competed using oligonucleotides containing
a consensus TEF-1 binding site as well as homologous
competitor DNAs. No significant diminishment was ob-
served using other competitors including an oligonucleo-
tide which contains a mutated TEF-1 site (TEF1MT). The
slight reduction seen with the Sp1 competitor was notFIG. 2. DNase I footprint analysis of the 128-bp enhancer region of
seen in other experiments and we do not believe it repre-HPV31 URR. A 228-bp fragment (nt 7333–7561, Fig. 1A), which contains
128-bp enhancer region (nt 7383 –7511) in the center, was end labeled sents significant activity. Furthermore, the faster migrat-
and incubated with or without SCC-13 nuclear extract followed by ing band was not diminished by any of the added compet-
DNase I digestion. The ladders of digested sense strand are shown itors and instead was enhanced following addition of a
in four lanes. The G / A lane contains chemically cleaved DNA as a
homologous competitor. These results suggest that themarker. The numbers and arrows shown on the left side are nucleotide
slower migrating band is a complex of TEF-1 and probepositions, and diminished bands with nuclear extract which are be-
lieved to correspond to footprint regions are indicated as closed dots. DNA, and the faster migrating band is due to a nonspe-
Open boxes indicate putative binding sites of YY1 and TEF-1 as identi- cific binding protein. Taken together these studies sug-
fied by sequence analysis.
gest that the footprints we observed in the 128-bp region
were due to the binding of YY1 and TEF-1.
to a transcriptional silencer in HPV6 (Roman et al., 1995) is present in the 5* end of the HPV31 URR. The inserts for luciferase reporter plasmids
were made by PCR with sites for ligation added to the ends of the fragments. Closed boxes on the 5* ends correspond to MluI sites, open boxes
on 3* ends correspond to BglII sites, and shaded boxes indicate BamHI linkers for deletions. (B–E) The results of transient expression assays
using two cell lines of squamous epithelial origin, SCC-13 (B, C), and CIN612 (D, E). Constructs using the homologous HPV31 p97 promoter are
shown in B and D. The luciferase activity of pGL3Basic was set to 1.0 and the relative luciferase activity of each plasmid is shown relative to that
value. The activity of pBas983 which contained the whole HPV31 URR was included as a control in each cell line tested. Enhancer reporter constructs
using the heterologous SV40 promoter are shown in C and E. The luciferase activity of the pGL3Promoter plasmid was normalized to 1.0 and
relative luciferase activity of each plasmid is shown. The data are shown as an average with a standard deviation, and statistic analyses are
performed with Student t test to detect the significant difference with the controls. NS; nothing significant, *P  0.05; **P  0.01; ***P  0.001.
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FIG. 3. The sense strand of HPV31 and the sequences of oligonucleotides for EMSAs. Closed circles are the nucleotide positions of diminished
bands in DNase I footprint analysis, and the outlined regions indicate putative binding sites for YY1 and TEF-1. EMSA probe 1–4 cover the binding
sites of YY1 1–3 and TEF-1, respectively, and footprint regions are also included in these probes. The mutations introduced for competition EMSA
assays are shown in small letters.
YY1 works as a transcriptional activator in the 128-bp that there is no significant effect of TEF-1 on the tran-
scriptional activation ability of the 128-bp enhancer.enhancer region
The 128-bp enhancer region augments theWe next sought to determine the contribution of YY1
transcriptional activity of the minimum enhancerand TEF-1 binding to the transcriptional enhancer activity
of the 128-bp fragment. To test the contribution of these To determine how the 128-bp enhancer region inter-
factors, luciferase reporter plasmids were constructed acts with the adjacent minimum keratinocyte enhancer,
which contained the same mutated binding sites identi- we constructed luciferase reporter plasmids as shown
fied in the previous section (Fig. 5A). The results of these in Fig. 6A. The results of luciferase assays using these
assays are shown in Figs. 5B and 5C. Mutation of binding plasmids are shown in Fig. 6B. The activity of the 128-
bp enhancer region (pPro128 (nt 7383–7511)) was aboutsite 1 of YY1 (YY1 1MT) had no significant effect on
2.6-fold higher than control, and duplication of this frag-expression when examined either in the context of the
ment (pPro128w) only modestly increased activity. Theentire URR (pBasYY1 1MT) or when placed upstream of
minimum keratinocyte enhancer (Kyo et al., 1995) washeterologous SV40 promoter (pProYY1 1MT). In contrast,
previously shown to exhibit the primary transcriptionalmutation of either binding site 2 or 3 (YY1 2MT and YY1
enhancer activity in the HPV31 URR (261 bp; nt 7511–3MT) resulted in significant decreased activity. When all
7772). When examined in SCC-13 cells, the activity ofthree YY1 binding sites were mutated, activity was dimin-
pPro261 was about 3.6-fold higher than control. In con-ished to background in the heterologous promoter re-
trast, the activity of the combined region of 128-bp en-porters (pProAllYY1MT). Mutation of all three YY1 sites
hancer and minimum enhancer (pPro389 (nt 7383–7772))in the plasmid using the p97 promoter (pBasAllYY1MT)
exhibited 8.0-fold activation. These findings suggest thatcaused reduced activity to a level which is slightly higher
the function of 128-bp region may be to provide an addi-than pBas128del. It is possible that this activity is due to
tive or slightly synergistic interaction with the minimumsome uncharacterized activity which functions together
keratinocyte enhancer to allow for maximum transcrip-with YY1 to augment URR expression. These findings
tional activation of the HPV31 URR early promoter.suggest that YY1 functions as a positive activator of the
128-bp enhancer region. The effect of the TEF-1 binding
DISCUSSIONsite mutation (TEF1MT) was to only slightly reduce ex-
pression relative to pBas983 and had no effect on the In this study, we have investigated the role of the 5*
portion of the HPV31 URR in regulating viral gene expres-pPro128 plasmid. From these observations, we conclude
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FIG. 4. Electrophoretic mobility shift assays of the putative binding sites of YY1 1 (A), YY1 2 (B), YY1 3 (C), YY1 1–3, with consensus YY1 (D),
and TEF-1 (D). The probes, competitors, and antibodies are described under Materials and Methods or in the legend to Fig. 3. The oligonucleotides
for consensus binding sites of AP-1, Oct-1, NFI, and Sp1, and the antibodies of Oct-1 and Sp1 were used as negative controls. B, specific retarded
band with nuclear extract; F, unbound free probe; S, supershifted band with antibody; N, nonspecific shifted band.
sion. Previous studies in HPV6 had identified a negative three YY1 and one TEF-1 binding sites as first identified
through sequence analysis and confirmed with DNase Iregulatory element or silencer in this region which was
localized to a 66-bp stretch of alternating thymidine and footprint analysis. Use of EMSAs further confirmed that
the putative binding sites actually bound these factors.purine nucleotides. A similar sequence is present in the
5* portion of the HPV31 URR, but does not exhibit signifi- Mutation of the binding sites for YY1 revealed that two
of these sites were important for enhancer function, whilecant down-regulation of homologous or heterologous
promoters in transient assays. Upon further examination the third YY1 site and TEF-1 site were not important. The
enhancer region is upstream of the minimum enhancerof this region, a positive enhancer of HPV31 early expres-
sion was identified which was located between nt 7383 (261 bp; nt 7511–7772), and our studies revealed additive
or slightly synergistic interaction between these two ele-and 7511. This region is adjacent to the previously identi-
fied minimum keratinocyte enhancer and acts to aug- ments (Fig. 6B). Thus the 128-bp enhancer region is prob-
ably a part of constitutive enhancer of HPV31 URR, andment its activity. This 128-bp enhancer could function by
itself as an enhancer but was most effective when it YY1 plays a important role in its regulation. Previously,
studies had identified the binding AP-1 to be importantacted together with the minimum enhancer region.
The 128-bp enhancer region was found to contain for the activity of the keratinocyte enhancer (Kyo et al.,
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FIG. 5. Transient expression assays using reporter plasmids containing mutated binding sites were performed to detect the contribution of each
binding site to the transcriptional activity. (A) Plasmids containing mutated binding sites. Each mutation was made with the same mutated binding
site oligonucleotide which was used in EMSA as a competitor. The mutation for each binding site is shown as a crossed-out box. Closed boxes
on 5* ends indicate MluI sites, open boxes on 3* ends correspond to BglII sites. (B) The luciferase activities of plasmids containing mutated binding
sites in the context of the entire URR and using the homologous HPV31 p97 promoter. The luciferase activity of pGL3Basic was set to 1.0 and the
relative luciferase activity of each plasmid is shown. The activity of pBas983 containing the whole HPV31 URR was used as a control. (C) The
results of luciferase activities of 128-bp enhancer mutants cloned upstream of the SV40 promoter. The luciferase of pGL3Promoter was normalized
to 1.0 and the relative luciferase activity of each plasmid is shown, and the activity of pPro128 which had 128-bp novel enhancer segment without
mutation is used as a control. P values of Student t test to detect the significant difference with the control are shown; NS, nothing significant; *P
 0.05; **P  0.01; ***P  0.001.
1995, 1997). Our results suggest that the complete HPV31 CIN612, we do not believe E2 provides a significant effect
on the activity of the 128-bp enhancer.enhancer region extends for about 400 bp (nt 7440–7840)
and is dependent upon both YY1 and AP-1 for activity. YY1 is an interesting transcriptional factor which can
function as either a repressor or an activator dependingThe 128-bp region also contains a single E2 binding site
and it is possible that this site contributes to the en- on the promoter context as well as its interaction with
other factors. Previous studies have demonstrated a rolehancer activity in CIN612 cells. However, since the level
of reduction in pBas128del is similar in both SCC-13 and for YY1 as a repressor of HPV16 expression (O’Connor
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FIG. 6. Interaction between the 128-bp enhancer and the minimum enhancer. (A) Luciferase reporter constructs utilizing the SV40 promoter. The
inserts of pPro128 (128-bp enhancer), pPro261 (minimum enhancer), pPro389 (combined segment of 128-bp and minimum enhancer), and pPro128w
(two tandem repeat of 128-bp enhancer) were made by PCR and restriction sites were introduced at the ends of the fragments. Closed boxes on
5* ends indicate MluI sites, open boxes on 3* ends correspond to BglII sites. The shaded box in the pPro128w plasmid corresponds to an EcoRI
site. (B) The result of luciferase assays using the 128-bp and minimum enhancer. The luciferase activity of the pGL3Promoter was set to 1.0 and
the relative luciferase activity of each plasmid is shown. P values of Student t test were calculated to detect the significant differences of the activity
between pPro128 vs pPro128w, pPro128 vs pPro389, and pPro261 vs pPro389. *P  0.05; **P  0.01; ***P  0.001.
et al., 1996). In contrast, Bauknecht et al. (1996) reported have suggested that this region acts to posttranscription-
ally regulate late gene expression perhaps through thea complex of YY1 with C/EBP-b functioned as a transcrip-
tional activator by binding to a keratinocyte-specific action of an instability element (Kennedy et al., 1991).
Additional studies will be required to further elucidate‘‘switch region’’ in HPV18 URR. It is not clear if the ele-
ments we have identified bind a similar complex; how- the role of this region.
In summary, we have determined that sequences inever, the binding sites of YY1 identified in the 128-bp
the 5* region of HPV31 URR act as enhancers of earlyenhancer do not correspond to binding sites for other
viral expression and augment the activity of the minimumknown factors. YY1 may act by itself in activation of the
keratinocyte enhancer. The factor YY1 was found to play128 bp or function synergistically with other unidentified
an important role for activation of this element and mayfactors. In either case, our studies demonstrate that YY1
act through interactions with other factors. These findingsis important for the enhancer activity of the 128-bp frag-
are consistent with the hypothesis that it is the combina-ment.
torial action of ubiquitous cellular factors that are respon-The 236-bp region at the 5* end of the URR contains
sible for the activation of HPV early gene expression.a long thymidine–purine alternating sequence which is
similar to a transcriptional silencer reported in HPV 6 ACKNOWLEDGMENTS
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